The potential of urine for human papillomavirus-related cervical cancer prevention

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Gupta G, Glueck R, Patel PR. HPV vaccines: global perspectives. Hum. Vaccines Immunother. 13(6), 1–4 (2017).
  MedlineGoogle Scholar
• 3. Sawaya GF, Smith-Mccune K, Kuppermann M. Cervical cancer screening: more choices in 2019. J. Am. Med. Assoc. 321(20), 2018–2019 (2019).
  Google Scholar
• 4. Ronco G, Dillner J, Elfström KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (London, England) 383(9916), 524–532 (2014).
  MedlineGoogle Scholar
• 5. Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 98–108 (2020).
  MedlineGoogle Scholar
• 6. Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organization call for action to eliminate cervical cancer globally. Int. J. Gynecol. Cancer 30(4), 426–427 (2020).
  MedlineGoogle Scholar
• 7. Brisson M, Kim JJ, Canfell K et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395(10224), 575–590 (2020).
  MedlineGoogle Scholar
• 8. Lorenzi AT, Fregnani JHT, Dockter J et al. High-risk human papillomavirus detection in urine samples from a referral population with cervical biopsy-proven high-grade lesions. J. Low. Genit. Tract Dis. 22(1), 17–20 (2018).
  MedlineGoogle Scholar
• 9. Nagendiram A, Bougher H, Banks J, Hall L, Heal C. Australian women's self-perceived barriers to participation in cervical cancer screening: a systematic review. Heal. Promot. J. Aust. 31(3), 343–353 (2020).
  MedlineGoogle Scholar
• 10. Devarapalli P, Labani S, Nagarjuna N, Panchal P, Asthana S. Barriers affecting uptake of cervical cancer screening in low and middle income countries: a systematic review. Indian J. Cancer 55(4), 318–326 (2018).
  MedlineGoogle Scholar
• 11. Ducancelle A, Reiser J, Pivert A, Le Guillou-Guillemette H, Le Duc-Banaszuk AS, Lunel-Fabiani F. Home-based urinary HPV DNA testing in women who do not attend cervical cancer screening clinics. J. Infect. 71(3), 377–384 (2015).
  MedlineGoogle Scholar
• 12. Ørnskov D, Jochumsen K, Steiner PH, Grunnet IM, Lykkebo AW, Waldstrøm M. Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for hpv testing among women referred for colposcopy. a cross-sectional study. BMJ Open 11(3), e041512 (2021).
  MedlineGoogle Scholar
• 13. Lefeuvre C, Pivert A, Le Guillou-Guillemette H et al. Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France. J. Infect. 81(2), 248–254 (2020).
  Medline CASGoogle Scholar
• 14. Daponte A, Michail G, Daponte A-I et al. Urine HPV in the context of genital and cervical cancer screening – an update of current literature. Cancers (Basel) 13(7), 1640 (2021).
  Medline CASGoogle Scholar
• 15. Fappani C, Bianchi S, Panatto D et al. HPV type-specific prevalence a decade after the implementation of the vaccination program: results from a pilot study. Vaccines 9(4), 336 (2021).
  CASGoogle Scholar
• 16. Shin HY, Lee B, Hwang SH et al. Evaluation of satisfaction with three different cervical cancer screening modalities: clinician-collected pap test vs HPV test by self-sampling vs HPV test by urine sampling. J. Gynecol. Oncol. 30(5), e76 (2019).
  Medline CASGoogle Scholar
• 17. Sy AU, Hernandez BY, Tareg A, Reichhardt M, Buenconsejo-Lum L. Acceptability and feasibility of a community based participatory research project comparing cytology and urine HPV DNA testing for cervical cancer screening in Yap, Federated States of Micronesia. Cancer Epidemiol. 50(Pt B), 283–288 (2017).
  MedlineGoogle Scholar
• 18. Huynh J, Howard M, Lytwyn A. Self-collection for vaginal human papillomavirus testing: systematic review of studies asking women their perceptions. J. Low. Genit. Tract Dis. 14(4), 356–362 (2010).
  MedlineGoogle Scholar
• 19. Cadman L, Reuter C, Jitlal M et al. A randomized comparison of different vaginal self-sampling devices and urine for human papillomavirus testing-predictors 5.1. Cancer Epidemiol. Biomarkers Prev. 30(4), 661–668 (2021).
  Medline CASGoogle Scholar
• 20. Rohner E, McGuire FH, Liu Y et al. Racial and ethnic differences in acceptability of urine and cervico–vaginal sample self-collection for HPV-based cervical cancer screening. J. Women's Heal. 29(7), 971–979 (2020).
  MedlineGoogle Scholar
• 21. Das BC, Gopalkrishna V, Sharma JK, Roy M, Luthra UK. Human papillomavirus DNA in urine of women with preneoplastic and neoplastic cervical lesions. Lancet 340(8832), 1417–1418 (1992).
  Medline CASGoogle Scholar
• 22. Mendez K, Romaguera J, Ortiz AP, López M, Steinau M, Unger ER. Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. Int. J. Gynecol. Obstet. 124(2), 151–155 (2014).
  Medline CASGoogle Scholar
• 23. Vergara N, Balanda M, Hidalgo W et al. Detection and genotyping of HPV in urine samples from Chilean women attending primary health care centers. Med. Microbiol. Immunol. 207(2), 95–103 (2018).
  Medline CASGoogle Scholar
• 24. Sabeena S, Kuriakose S, Binesh D et al. The utility of urine-based sampling for cervical cancer screening in low-resource settings. Asian Pacific J. Cancer Prev. 20(8), 2409–2413 (2019).
  Medline CASGoogle Scholar
• 25. Payan C, Ducancelle A, Aboubaker MH et al. Human papillomavirus quantification in urine and cervical samples by using the Mx4000 and LightCycler general real-time PCR systems. J. Clin. Microbiol. 45(3), 897–901 (2007).
  Medline CASGoogle Scholar
• 26. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 363, k4823 (2018).
  MedlineGoogle Scholar
• 27. Maged AM, Saad H, Salah E et al. Urine test for HPV genotypes as a predictor of precancerous cervical lesions and for cervical cancer screening. Int. J. Gynecol. Obstet. 141(3), 332–336 (2018).
  Medline CASGoogle Scholar
• 28. Stanczuk GA, Currie H, Baxter G et al. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment. J. Clin. Pathol. 68(7), 567–570 (2015).
  MedlineGoogle Scholar
• 29. Piyathilake CJ, Badiga S, Chambers MM, Brill IK, Matthews R, Partridge EE. Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia. Cancer 122(18), 2836–2844 (2016).
  Medline CASGoogle Scholar
• 30. Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. BMJ Open 9(4), e025388 (2019).
  MedlineGoogle Scholar
• 31. Rohner E, Rahangdale L, Sanusi B et al. Test accuracy of human papillomavirus in urine for detection of cervical intraepithelial neoplasia. J. Clin. Microbiol. 58(3), e01443–19 (2020).
  Medline CASGoogle Scholar
• 32. Cho H-W, Hong JH, Min KJ et al. Performance and diagnostic accuracy of human papillomavirus testing on self-collected urine and vaginal samples in a referral population. Cancer Res. Treat. 53(3), 829–836 (2021).
  Medline CASGoogle Scholar
• 33. Stanczuk G, Baxter G, Currie H et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway – PaVDaG study). BMJ Open 6(4), e010660 (2016).
  MedlineGoogle Scholar
• 34. Padhy RR, Davidov A, Madrigal L, Alcide G, Spahiu A. Detection of high-risk human papillomavirus RNA in urine for cervical cancer screening with HPV 16 and 18/45 genotyping. Heliyon 6(4), e03745 (2020).
  MedlineGoogle Scholar
• 35. Asciutto KC, Ernstson A, Forslund O, Borgfeldt C. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. J. Clin. Virol. 101, 69–73 (2018).
  Medline CASGoogle Scholar
• 36. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J. Natl Cancer Inst. Monogr. (31), 14–19 (2003).
  MedlineGoogle Scholar
• 37. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195(11), 1582–1589 (2007).
  MedlineGoogle Scholar
• 38. Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br. J. Cancer 122(11), 1577–1579 (2020).
  Medline CASGoogle Scholar
• 39. Vassilakos P, Wisniak A, Catarino R et al. A cross-sectional study exploring triage of human papillomavirus (HPV)-positive women by visual assessment, manual and computer-interpreted cytology, and HPV-16/18-45 genotyping in Cameroon. Int. J. Gynecol. Cancer 31(6), 808–816 (2021).
  MedlineGoogle Scholar
• 40. Kremer WW, Steenbergen RDM, Heideman DAM, Kenter GG, Meijer CJLM. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. Obstet. Gynecol. Surv. 128(3), 504–514 (2021).
  CASGoogle Scholar
• 41. Snoek BC, van Splunter AP, Bleeker MCG et al. Cervical cancer detection by DNA methylation analysis in urine. Sci. Rep. 9(1), 3088 (2019).
  MedlineGoogle Scholar
• 42. van den Helder R, van Trommel NE, van Splunter AP, Lissenberg-Witte BI, Bleeker MCG, Steenbergen RDM. Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection. Papillomavirus Res. 9, 100193 (2020).
  MedlineGoogle Scholar
• 43. Van Keer S, van Splunter AP, Pattyn J et al. Triage of human papillomavirus infected women by methylation analysis in first-void urine. Sci. Rep. 11(1), 7862 (2021).
  Medline CASGoogle Scholar
• 44. Safaeian M, Wright TC, Stoler MH et al. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Am. J. Obstet. Gynecol. 225(3), 278 (2021).
  MedlineGoogle Scholar
• 45. Østbye K, Pedersen M, Sauer T. Immunocytochemical expression of Ki-67/p16 in normal, atypical, and neoplastic cells in urine cytology using BD SurePath™ as preparation method. Cytojournal 16, 26 (2019).
  MedlineGoogle Scholar
• 46. Lamsisi M, Wakrim L, Bouziyane A et al. The biological significance of long noncoding RNAs dysregulation and their mechanism of regulating signaling pathways in cervical cancer. Int. J. Mol. Cell. Med. 10(2), 75–101 (2021).
  Medline CASGoogle Scholar
• 47. Sammarco ML, Tamburro M, Pulliero A, Izzotti A, Ripabelli G. Human papillomavirus infections, cervical cancer and MicroRNAs: an overview and implications for public health. MicroRNA 9(3), 174–186 (2019).
  Google Scholar
• 48. Causin RL, Da Silva LS, Evangelista AF et al. MicroRNA biomarkers of high-grade cervical intraepithelial neoplasia in liquid biopsy. Biomed Res. Int. 2021, 6650966 (2021).
  MedlineGoogle Scholar
• 49. Lamsisi M, Li G, Benhessou M et al. Long noncoding RNA HOTAIR as a biomarker for the detection of cervical cancer and cervical intraepithelial neoplasia. Indian J. Gynecol. Oncol. 2021 194 19(4), 1–8 (2021).
  Google Scholar
• 50. Barwal TS, Sharma U, Vasquez KM, Prakash H, Jain A. A panel of circulating long non-coding RNAs as liquid biopsy biomarkers for breast and cervical cancers. Biochimie 176, 62–70 (2020).
  Medline CASGoogle Scholar
• 51. Aftab M, Poojary SS, Seshan V et al. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer. Sci. Rep. 11(1), 10323 (2021).
  Medline CASGoogle Scholar
• 52. Luciani S, Bruni L, Agurto I, Ruiz-Matus C. HPV vaccine implementation and monitoring in Latin America. Salud Publica Mex. 60(6), 683–692 (2018).
  MedlineGoogle Scholar
• 53. Lowy DR, Herrero R, Hildesheim A et al. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 16(5), e226–233 (2015).
  MedlineGoogle Scholar
• 54. Group IHW. Primary End-points for Prophylactic HPV Vaccine Trials. (2014). https://www.ncbi.nlm.nih.gov/books/NBK304971/
  Google Scholar
• 55. Vorsters A, Van Keer S, Biesmans S et al. Long-term follow-up of HPV infection using urine and cervical quantitative HPV DNA testing. Int. J. Mol. Sci. 17(5), 750 (2016).
  Google Scholar
• 56. Cuschieri K, Nandwani R, McGough P et al. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J. Med. Virol. 83(11), 1983–1987 (2011).
  MedlineGoogle Scholar
• 57. Koene F, Wolffs P, Brink A et al. Comparison of urine samples and penile swabs for detection of human papillomavirus in HIV-negative Dutch men. Sex. Transm. Infect. 92(6), 467–469 (2016).
  MedlineGoogle Scholar
• 58. Aung ET, Fairley CK, Tabrizi SN et al. Detection of human papillomavirus in urine among heterosexual men in relation to location of genital warts and circumcision status. Sex. Transm. Infect. 94(3), 222–225 (2018).
  MedlineGoogle Scholar
• 59. Laake I, Feiring B, Jonassen CM et al. Concurrent infection with multiple human papillomavirus types among unvaccinated and vaccinated 17-year-old Norwegian girls. J. Infect. Dis. jiaa709 (2020).
  MedlineGoogle Scholar
• 60. Feiring B, Laake I, Christiansen IK et al. Substantial decline in prevalence of vaccine-type and nonvaccine-type human papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway. J. Infect. Dis. 218(12), 1900–1910 (2018).
  MedlineGoogle Scholar
• 61. Lehtinen T, Söderlund-Strand A, Petäjä T et al. Human papillomavirus (HPV) prevalence in male adolescents 4 years after HPV-16/18 vaccination. J. Infect. Dis. 216(8), 966–968 (2017).
  Medline CASGoogle Scholar
• 62. Franceschi S, Chantal Umulisa M, Tshomo U et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int. J. Cancer 139(3), 518–526 (2016).
  Medline CASGoogle Scholar
• 63. Baussano I, Sayinzoga F, Tshomo U et al. Impact of human papillomavirus vaccination, Rwanda and Bhutan. Emerg. Infect. Dis. 27(1), 1–9 (2021).
  MedlineGoogle Scholar
• 64. Carnalla M, Torres-Ibarra L, Barrientos-Gutiérrez T et al. Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes. Vaccine 39(32), 4419–4422 (2021).
  Medline CASGoogle Scholar
• 65. VK S, W-F M, J P et al. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. J. Clin. Virol. 117, 11–18 (2019).
  MedlineGoogle Scholar
• 66. Pattyn J, Panicker G, Willhauck-Fleckenstein M et al. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine. J. Med. Virol. 92(12), 3774–3783 (2020).
  CASGoogle Scholar
• 67. Pattyn J, Van Keer S, Téblick L, Van Damme P, Vorsters A. Non-invasive assessment of vaccine-induced HPV antibodies via first-void urine. Front. Immunol. 11, 1657 (2020).
  Medline CASGoogle Scholar
• 68. Arbyn M, Peeters E, Benoy I et al. VALHUDES: a protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J. Clin. Virol. 107, 52–56 (2018).
  Medline CASGoogle Scholar
• 69. Pattyn J, Van Keer S, Biesmans S et al. Human papillomavirus detection in urine: effect of a first-void urine collection device and timing of collection. J. Virol. Methods 264, 23–30 (2019).
  Medline CASGoogle Scholar
• 70. Senkomago V, Des Marais AC, Rahangdale L, Vibat CRT, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J. Clin. Virol. 74, 26–31 (2016).
  Medline CASGoogle Scholar
• 71. Vorsters A, Van den Bergh J, Micalessi I et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur. J. Clin. Microbiol. Infect. Dis. 33(11), 2005–2014 (2014).
  Medline CASGoogle Scholar
• 72. Hernandez-Lopez R, Hermosillo L, Leon-Maldonado L et al. Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women. PLoS ONE 6(7), e0254946 (2021).
  Google Scholar
• 73. Guo X, Wang H, You R et al. Elimination of human cytomegalovirus DNA degradation in urine. J. Med. Virol. 93(8), 5033–5039 (2021).
  Medline CASGoogle Scholar
• 74. Arias M, Jang D, Dockter J et al. Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA. J. Virol. Methods 267, 48–52 (2019).
  Medline CASGoogle Scholar
• 75. Téblick L, Van Keer S, De Smet A et al. Impact of collection volume and DNA extraction method on the detection of biomarkers and HPV DNA in first-void urine. Molecules 26(7), 1989 (2021).
  Medline CASGoogle Scholar
• 76. Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J. Am. Soc. Cytopathol. 8(5), 284–292 (2019).
  MedlineGoogle Scholar
• 77. Cho HW, Ouh YT, Hong JH et al. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. J. Virol. Methods 269, 77–82 (2019).
  Medline CASGoogle Scholar
• 78. Lim MC, Lee DH, Hwang SH et al. Comparison of the Abbott RealTime High Risk HPV test and the Roche cobas 4800 HPV test using urine samples. J. Virol. Methods 243, 74–79 (2017).
  Medline CASGoogle Scholar
• 79. Tranberg M, Jensen JS, Bech BH, Andersen B. Urine collection in cervical cancer screening – analytical comparison of two HPV DNA assays. BMC Infect. Dis. 20(1), 926 (2020).
  Medline CASGoogle Scholar
• 80. Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. Commercially available molecular tests for human papillomaviruses: a global overview. Clin. Microbiol. Infect. 26(9), 1144–1150 (2020).
  Medline CASGoogle Scholar
• 81. Lee HJ, Choi M, Hwang SH, Cho Y. A versatile nanowire platform for highly efficient isolation and direct PCR-free colorimetric detection of human papillomavirus DNA from unprocessed urine. Theranostics 8(2), 399–409 (2018).
  Medline CASGoogle Scholar
• 82. Lee HJ, Choi M, Jo M, Park EY, Hwang SH, Cho Y. Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine. Gynecol. Oncol. 156(3), 641–646 (2020).
  Medline CASGoogle Scholar
• 83. Díaz de León-Martínez L, Flores-Ramírez R, Miguel López-Mendoza C et al. Identification of volatile organic compounds in the urine of patients with cervical cancer. test concept for timely screening. Clin. Chim. Acta. 522, 132–140 (2021).
  MedlineGoogle Scholar
• 84. Wentzensen N, Clarke MA, Perkins RB. Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities. Prev. Med. (Baltim). 151, 106596 (2021).
  Google Scholar
• 85. Chavan S, Mangalaparthi KK, Singh S et al. Mass spectrometric analysis of urine from COVID-19 patients for detection of SARS-CoV-2 viral antigen and to study host response. J. Proteome Res. 20(7), 3404–3413 (2021).
  Medline CASGoogle Scholar
• 86. Fozouni P, Son S, Díaz de León Derby M et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184(2), 323–333.e9 (2021).
  Medline CASGoogle Scholar
• 87. Hartanto H, Wu M, Lam ML, Chen TH. Microfluidic immunoassay for detection of serological antibodies: a potential tool for rapid evaluation of immunity against SARS-CoV-2. Biomicrofluidics 14(6), 061507 (2020).
  Medline CASGoogle Scholar